BioCentury | Jul 21, 2014
Clinical News

CTP-354: Phase I ongoing

...clinical hold on CTP-354 after the company completed preclinical toxicology studies testing repeated doses of CTP-354...
...of an additional higher dose. This quarter, Concert plans evaluate a 12 mg/day dose of CTP-354...
...spasticity associated with spinal cord injury. Concert Pharmaceuticals Inc. (NASDAQ:CNCE), Lexington, Mass. Product: CTP-354 (formerly C-21191...
BioCentury | Feb 14, 2014
Financial News

Concert raises $84 million in IPO

...with data expected this half. Next half, Concert plans to start Phase II testing of CTP-354...
...multiple sclerosis (MS) and spinal cord injury; and AVP-786 for treatment-resistant major depressive disorder (MDD). CTP-354...
BioCentury | Feb 4, 2014
Financial News

Concert sets IPO terms

...with data expected this half. Next half, Concert plans to start Phase II testing of CTP-354...
...multiple sclerosis (MS) and spinal cord injury; and AVP-786 for treatment-resistant major depressive disorder (MDD). CTP-354...
BioCentury | Jun 17, 2013
Clinical News

CTP-354: Phase I started

...ascending-doses of CTP-354 in healthy volunteers. Concert Pharmaceuticals Inc. , Lexington, Mass. Product: CTP-354 (formerly C-21191...
BioCentury | Mar 12, 2012
Company News

Concert Pharmaceuticals, National Multiple Sclerosis Society neurology news

...subsidiary committed up to $750,000 to fund preclinical development of Concert's spasticity and pain candidate C-21191...
Items per page:
1 - 5 of 5